PREDICTION OF ADVERSE EFFECTS OF AMIODARONE BY SIGNAL AVERAGING IN HCM PATIENTS

通过 HCM 患者的信号平均来预测胺碘酮的不良反应

• 批准号: 3920190
• 负责人: L FANANAPAZIR
• 金额: --
• 依托单位: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3920190
• 关键词: antiarrhythmic agent; drug adverse effect; electrocardiography; electrophysiology; heart disorder chemotherapy; human subject; hypertrophic myocardiopathy; noninvasive diagnosis; sudden cardiac death; tachycardia

Analysis of the terminal portion of the QRS of the ECG and detection of late potential (LP) by signal averaging (SAE) is a noninvasive method for identifying patients who are prone to develop ventricular tachycardia (VT) and are therefore at risk for sudden cardiac death. We have earlier shown that there was a and correlation between the presence of LP and inducibility of VT in patients with hypertrophic cardiomyopathy (HCM). Amiodarone is a patient antiarrhythmic drug. The purpose of the present investigation was to determine whether changes in SAE predicted efficacy and proarrhythmic potential in 14 HCM patients treated with amiodarone. Amiodarone increased the incidence of LP. This was associated with the greater ease with which VT was induced during programmed electrical stimulation. Thus SAE may identify HCM patients in whom amiodarone is proarrhythmic and may be at increased risk for sudden cardiac death.

分析ECG的QRS的末端部分， 通过信号平均（SAE）检测晚电位（LP）是一种 一种非侵入性的方法，用于识别 发生室性心动过速（VT），因此有风险 心源性猝死 我们之前已经证明，有一个和 LP的存在与VT的诱导之间的相关性 肥厚型心肌病（HCM）患者。 胺碘酮是一种 患者抗抑郁药。 编写本 研究旨在确定SAE的变化是否可预测 14例肥厚型心肌病患者的疗效和预防潜力 胺碘酮 胺碘酮可增加LP的发生率。 这 与诱发室性心动过速的容易程度相关 在编程的电刺激期间。 因此，SAE可以识别 胺碘酮具有促肾上腺皮质激素作用且可能 增加心脏性猝死的风险。